EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Top 10 List of Boston-Area VC Deals for Q4 2010: NinePoint, 1366, Rive, and More

The venture financing stats from the fourth quarter of 2010 continue to trickle in. Here are the 10 biggest equity financing deals of the quarter in the Boston area, according to the MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based on data from Thomson Reuters. (You can also check out today’s national commentary from Flybridge Capital Partners’ Michael Greeley here.)

The financing amounts are based on MoneyTree’s bookkeeping standards (reports will differ); investors listed below are those named in the report:

—NinePoint Medical, $27.8 million; Prospect Venture Partners, Third Rock Ventures

—1366 Technologies, $26 million; North Bridge Venture Partners, Polaris Venture Partners, Ventizz Capital Partners

—Rive Technology, $25 million; Advanced Technology Ventures, Blackstone Group, Charles River Ventures, Nth Power

—Proteostasis Therapeutics, $23 million; Beacon Bioventures, HealthCare Ventures

—InfraReDx, $21.3 million; GMP Securities, Sanderling Ventures

—Heartland Robotics, $20 million; Bezos Expeditions, Charles River Ventures, Highland Capital Partners, Sigma Partners, Staenberg Venture Partners

—Civitas Therapeutics, $20 million; Canaan Partners, Longitude Capital Management

—Karyopharm Therapeutics, $20 million; Bessemer Venture Partners

—Care.com, $20 million; Matrix Partners, New Enterprise Associates, Trinity Ventures

—Semprus Biosciences, $18 million; 5AM Ventures, Foundation Medical Partners, Pangaea Ventures, S.R. One

A few other notable deals that didn’t quite make the Top 10: SCVNGR ($17 million), Cerulean Pharma ($16.5 million), and Verastem ($16 million).

Trending on Xconomy

The Author

Gregory T. Huang is Xconomy's Deputy Editor, National IT Editor, and the Editor of Xconomy Boston. You can e-mail him at gthuang@xconomy.com.